Why is PCOS Getting a Name Change?

The condition long known as polycystic ovary syndrome (PCOS) has been renamed polyendocrine metabolic ovarian syndrome (PMOS) to better reflect its complex endocrine, metabolic, reproductive, and mental health effects. The name change highlights a growing recognition that this condition extends far beyond ovarian findings and requires a more comprehensive approach to diagnosis, treatment, and long-term risk management. You will be better prepared to understand the rationale behind the new terminology and support patients through evidence-based management of this multifaceted condition.HOSTRachel Maynard, PharmDGameChangers Podcast Host and Lead, Clinical & Partnership Education, CEimpactGUESTErin Raney, PharmD, BCPSProfessorMidwestern University College of PharmacyGET CE FOR LISTENING!Stay Compliant. Grow Clinically. Practice with Confidence. Pharmacist CE Subscription: All your CE in one convenient subscription.All episodes, CE, and Practice Resources for the GameChangers Clinical Update is included with your Pharmacist CE Subscription. But wait…there’s even more!The Pharmacist CE Subscription includes: -  Compliance and licensure CE -  GameChangers Clinical Updates-  Practical continuing education across patient care topics *The subscription does not include microcredentials or certificates, which are available separately for pharmacists seeking specialized service training. Purchase Now!PRACTICE RESOURCEReceive the exclusive Practice Resource to use as a reference guide for this episode by purchasing the Pharmacist CE Subscription. CPE REDEMPTIONThis course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation to claim credit:If you are already enrolled in this course, click here to redeem your credit. To purchase the Pharmacist CE Subscription and claim your CPE credit, click here or to purchase this course individually, click here.  CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Describe the rationale for the transition from polycystic ovary syndrome (PCOS) to polyendocrine metabolic ovarian syndrome (PMOS).2. Explain the endocrine, metabolic, and reproductive features that influence the management of PMOS.Rachel Maynard and Erin Raney have no relevant financial relationships to disclose.0.075 CEU/0.75 HrUAN: 0107-0000-26-314-H01-PInitial release date: 8/24/2026Expiration date: 8/24/2029Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram